126 related articles for article (PubMed ID: 11516800)
21. Comparison of treatment outcomes of infertile women by clomiphene citrate and letrozole with gonadotropins underwent intrauterine insemination.
Zadehmodares S; Niyakan M; Sharafy SA; Yazdi MH; Jahed F
Acta Med Iran; 2012; 50(1):18-20. PubMed ID: 22267373
[TBL] [Abstract][Full Text] [Related]
22. Heterotopic pregnancy following ovulation induction by clomiphene citrate and timed intercourse: a case report.
Naki MM; Tekcan C; Uysal A; Güzin K; Yücel N
Arch Gynecol Obstet; 2006 Jun; 274(3):181-3. PubMed ID: 16463167
[TBL] [Abstract][Full Text] [Related]
23. Long-term effects of ovulation-stimulating drugs on cancer risk.
Brinton L
Reprod Biomed Online; 2007 Jul; 15(1):38-44. PubMed ID: 17623533
[TBL] [Abstract][Full Text] [Related]
24. Perinatal outcomes in 6,338 singletons born after intrauterine insemination in Denmark, 2007 to 2012: the influence of ovarian stimulation.
Malchau SS; Loft A; Henningsen AK; Nyboe Andersen A; Pinborg A
Fertil Steril; 2014 Oct; 102(4):1110-1116.e2. PubMed ID: 25064412
[TBL] [Abstract][Full Text] [Related]
25. Modelling body mass index and endometrial cancer risk in a pooled-analysis of three case-control studies.
Rota M; Rumi F; Bagnardi V; Dal Maso L; Zucchetto A; Levi F; La Vecchia C; Tavani A
BJOG; 2016 Jan; 123(2):285-92. PubMed ID: 26541752
[TBL] [Abstract][Full Text] [Related]
26. Cancer incidence in a cohort of infertile women.
Modan B; Ron E; Lerner-Geva L; Blumstein T; Menczer J; Rabinovici J; Oelsner G; Freedman L; Mashiach S; Lunenfeld B
Am J Epidemiol; 1998 Jun; 147(11):1038-42. PubMed ID: 9620047
[TBL] [Abstract][Full Text] [Related]
27. Ovarian hyperstimulation syndrome associated with clomiphene citrate.
Mitchell SY; Fletcher HM; Williams E
West Indian Med J; 2001 Sep; 50(3):227-9. PubMed ID: 11769032
[TBL] [Abstract][Full Text] [Related]
28. Intra-uterine contraception and the risk of endometrial cancer.
Castellsagué X; Thompson WD; Dubrow R
Int J Cancer; 1993 Jul; 54(6):911-6. PubMed ID: 8335399
[TBL] [Abstract][Full Text] [Related]
29. The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up.
Kessous R; Davidson E; Meirovitz M; Sergienko R; Sheiner E
J Cancer Res Clin Oncol; 2016 Jan; 142(1):287-93. PubMed ID: 26337160
[TBL] [Abstract][Full Text] [Related]
30. In situ and invasive cervical carcinoma in a cohort of infertile women.
Rossing MA; Daling JR; Weiss NS; Moore DE; Self SG
Fertil Steril; 1996 Jan; 65(1):19-22. PubMed ID: 8557140
[TBL] [Abstract][Full Text] [Related]
31. The evaluation of the data collection process for a multicenter, population-based, case-control design.
Wingo PA; Ory HW; Layde PM; Lee NC
Am J Epidemiol; 1988 Jul; 128(1):206-17. PubMed ID: 3381827
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer among young U.S. women in relation to oral contraceptive use.
White E; Malone KE; Weiss NS; Daling JR
J Natl Cancer Inst; 1994 Apr; 86(7):505-14. PubMed ID: 8133534
[TBL] [Abstract][Full Text] [Related]
33. A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group.
Gruber SB; Thompson WD
Cancer Epidemiol Biomarkers Prev; 1996 Jun; 5(6):411-7. PubMed ID: 8781735
[TBL] [Abstract][Full Text] [Related]
34. Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study.
Reigstad MM; Storeng R; Myklebust TÅ; Oldereid NB; Omland AK; Robsahm TE; Brinton LA; Vangen S; Furu K; Larsen IK
Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):953-962. PubMed ID: 28108444
[No Abstract] [Full Text] [Related]
35. Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea.
Hughes E; Collins J; Vandekerckhove P
Cochrane Database Syst Rev; 2000; (2):CD000056. PubMed ID: 10796477
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment and co-administration of oral anti-diabetic agent with clomiphene citrate or rFSH for ovulation induction in clomiphene-citrate-resistant polycystic ovary syndrome.
Begum MR; Akhter S; Ehsan M; Begum MS; Khan F
J Obstet Gynaecol Res; 2013 May; 39(5):966-73. PubMed ID: 23379651
[TBL] [Abstract][Full Text] [Related]
37. Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai.
Xu WH; Xiang YB; Ruan ZX; Zheng W; Cheng JR; Dai Q; Gao YT; Shu XO
Int J Cancer; 2004 Feb; 108(4):613-9. PubMed ID: 14696129
[TBL] [Abstract][Full Text] [Related]
38. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico.
Salazar-Martinez E; Lazcano-Ponce EC; Gonzalez Lira-Lira G; Escudero-De los Rios P; Salmeron-Castro J; Hernandez-Avila M
Cancer Res; 1999 Aug; 59(15):3658-62. PubMed ID: 10446978
[TBL] [Abstract][Full Text] [Related]
39. Risk factors among young women with endometrial cancer: a Danish case-control study.
Parslov M; Lidegaard O; Klintorp S; Pedersen B; Jønsson L; Eriksen PS; Ottesen B
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):23-9. PubMed ID: 10649152
[TBL] [Abstract][Full Text] [Related]
40. Aromatase inhibitors for subfertile women with polycystic ovary syndrome.
Franik S; Kremer JA; Nelen WL; Farquhar C
Cochrane Database Syst Rev; 2014 Feb; (2):CD010287. PubMed ID: 24563180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
